Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nycomed puts in “satisfactory performance” in Q3

Nycomed puts in “satisfactory performance” in Q3

13th November 2009

Nycomed performed in a “satisfactory” manner during the third quarter of 2009, it has been stated.

This is according to the firm’s chief executive officer Hakan Bjorklund, who made the comments upon the release of the company’s financial results this week.

The figures show that Nycomed’s total net turnover increased by 0.9 per cent during the period to 820 million euros (734 million pounds).

Additionally, sales of pantoprazole remained resilient during this timeframe and the organisation’s breakthrough cancer pain drug Instanyl was approved in the EU.

Mr Bjorklund stated: “Furthermore, the positive phase III trial results were published in the medical journal The Lancet and presented at the European Respiratory Society meeting in Vienna.”

In September, Nycomed announced plans to invest up to 75 million euros (68 million pounds) into a brand new cutting-edge pharmaceutical production plant in Russia.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.